Discussion: Current Clinical Management of Peptic Ulcer Disease by Berlin, Roger G.
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 65 (1992), 689-692
Current Clinical Management ofPeptic Ulcer Disease
ROGER G. BERLIN, M.D.
The papers presented in this section highlight some of the recent advances in
understanding the pathogenesis of peptic ulcer disease, its therapeutics through
control of acid secretion, and the implications of hypergastrinemia produced by
perturbations in the feedback loop controlling the release ofgastrin from the antral
G cell. Each paper simultaneously illustrates the sophistication of our knowledge
and, in counterpoint, our ignorance. While the application of20 leeches to the anus
as described by Cruveilhier in the seventeenth century has fallen out of favor as
accepted ulcer therapy, the choice ofa therapeutic agent is still controversial.
Illustrative of these issues is the role ofHelicobacterpylori in the pathogenesis of
peptic ulcer and its relapse and the potential therapeutic implications ofits eradica-
tion. This organism, reported in the late 1800s as a urea-producing gastricbacterium
and rediscovered byWarren [1] and Marshall [2,3] has had a significant effect on our
understanding of the pathogenesis of type B gastritis, peptic ulcer and its relapse,
and putatively on the etiology ofgastric adenocarcinoma. Ingestion of the organism
has been shown to lead to acute gastritis, and eradication of the organism with
treatment has been associated with the diminution of gastritis [4]. As discussed by
Halter et al., the organism elaborates a number of substances, including chemotac-
tants for PMNs and monocytes [5] that are thought to contribute to the development
ofan acute gastritis.
Most evidence for the etiologic role ofHelicobacterpylori in peptic ulcer disease is
indirect. Since Helicobacter colonization is much more common than peptic ulcer
disease and does not follow the age and gender distribution of ulcer disease, other
factors such as host susceptibility or differences in strain virulence would have to be
invoked. Nonetheless, it is clear that eradication of Helicobacter pyloni leads to a
dramatic reduction in duodenal ulcer relapse [6]. Although this approach is not the
current standard of care, the ability to cure rather than to treat duodenal ulcer and
thus to convert a chronic illness into an acute disease will make this approach
inescapable, particularlywhen improved anti-Helicobacter therapies are available.
While the cause of gastric cancer is likely multifactorial, recent epidemiologic
studies have suggested that Helicobacter infection, presumably acting through the
induction ofgastritis, may account for approximately 60 percent ofthese cancers [7].
While this datum is still controversial, the importance of eradication ofHelicobacter
may take on even greater importance than noted above for duodenal ulcer.
All of these considerations suggest that effective, well-tolerated therapy that
consistently eradicatesHelicobacterwill allow a clarification ofthe role ofHelicobac-
terin these diseases. The current regimen oftriple therapy haslimitations in terms of
toleration, convenience, and the development ofmicrobial resistance. In vitro studies
suggest that the proton pump inhibitors omeprazole [8] and lansoprazole [9] have
anti-Helicobacter activity, and preliminary studies with omeprazole and amoxicillin
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suggest promise for such a combination. Yet to be explored are therapies based on
interference with unique Helicobacter pathways or Helicobacter host interactions,
such as adherence, that may be essential to establish or maintain infection.
The directed search for a histamine H2-receptor antagonist performed by Sir
James Black and collaborators resulted in the discovery ofcimetidine [10]. As noted
by Marks, this compound, when introduced in 1976-77, revolutionized the treatment
of peptic ulcer disease, which previously had been limited to antacids, anticholiner-
gics, and diet. While the imidazole ring had been deemed critical, the subsequent
development of H2-receptor antagonists with a furan ring, ranitidine, or with a
thiazole ring, famotidine, and nizatidine, disproved that assumption. Cloning of the
H2-receptor [11], a typical G protein-linked transmembrane receptor, has permitted
characterization ofthe manner in which ligands bind to the H2-receptor.
H2-receptor antagonists permitted the demonstration of the predominant physio-
logic role of histamine in stimulating gastric acid secretion by their ability to inhibit
acid secretion stimulated by a wide variety of compounds, including gastrin and
cholinergic agonists. Equally revolutionary was the in-depth knowledge of the
natural history of ulcer disease provided by large-scale controlled trials, which
included endoscopic assessment of the state of healing. Multiple studies have
demonstrated the efficacy of these drugs in the treatment of peptic ulcer disease,
maintenance therapy, and, more recently, in the treatment of gastroesophageal
reflux disease. H2-receptor antagonists have been shown to be extremely well
tolerated despite thewide distribution ofH2-receptors in many organs other than the
stomach. In fact, given the excellent safety profile of these agents and the trend
toward self-directed therapy, these agents are likely candidates for over-the-counter
use for symptomatic relief.
Inhibition of the terminal step of acid production in the parietal cell, the
H+/K+-ATPase located on the membrane of the secretory canaliculus, is the most
recent therapeutic target. The proton pump was described in 1973 [12], and
subsequent studies have elucidated the amino acid sequence, a three-dimensional
model demonstratingmultiplemembrane-spanning domains, and the sites ofinterac-
tion with the enzyme inhibitor omeprazole, which acts to bind covalently at the H+
site, and SCH 28080, which acts reversibly at the K+ site [13].
The ability of the proton or acid pump inhibitors to reduce gastric acid secretion
profoundly has allowed us to understand better the clinical implications of such
reductions in the therapy of acid-related disorders. As discussed by Bell and Hunt, it
is now possible to model therapeutic response for duodenal ulcer disease versus the
duration and extent of elevation of intragastric pH to various levels [14]. For such
ulcers, a pH of 3 or more for 18 hours or longer predicts 100 percent healing after
four weeks of therapy. More recent data suggest that the critical intragastric pH for
the treatment of GERD is 4 or above. As expected from these data, omeprazole has
demonstrated superiority versus H2-receptor blockade in healing erosive or ulcer-
ative esophagitis, duodenal ulcer, NSAID-associated gastric ulcer, and is the drug of
choice for the treatment of Zollinger-Ellison syndrome (ZES) [15]. Of interest in
regard to the treatment of Helicobacter are the preliminary data that omeprazole,
when combined with amoxicillin, eradicates the organism in about 50-60 percent of
patients [16]. Further work is needed to confirm these findings and to define the
optimum regimen. Clinical experience suggests that omeprazole, like the H2-
receptor antagonists, has avery favorable tolerability profile. This outcome is at least
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partially predicted by the unique enzymatic target located only in the parietal cell
and by the fact that ionic trapping, concentration, and activation of the compound
occuronly in the acid compartment ofthe parietal cell target.
A controversy has affected the development of more potent anti-secretory agents
such asomeprazole. Thefindingofgastricendocrine tumorscomposedofenterochro-
maffin-like (ECL) cells in rats exposed to omeprazole in lifetime studies ignited
interest in the mechanism ofinduction ofthese tumors and ofthe physiologic role of
this cell. That this finding in rodents is not unique to omeprazole but results from
hypergastrinemia is supported by similar findings of ECL-cell carcinoids induced by
ranitidine, loxtidine, SKF93479, and by non-pharmacologically induced hypergas-
trinemia resulting from a 75 percent partial gastric corpectomy [17].
Hirschowitz presented data from studies in patients with pernicious anemia [18]
and with ZES [19] to illustrate that elevated gastrin levels, resulting from removal of
acid from the feedback loop controlling the release ofgastrin from the antral G cell
or from tumor-associated hypergastrinemia, respectively, may lead to ECL-cell
hyperplasia and ECL-cell carcinoid tumors. Rapid regression of gastric ECL-cell
carcinoids inpernicious anemiapatientsundergoing antrectomyfurther supports the
role of hypergastrinemia in causing these lesions [20]. Factors in addition to
hypergastrinemia alone, however, may be necessary for the formation of ECL
carcinoids, as evidenced by their occurrence predominantly in the subset of ZES
patients who have the multiple endocrine neoplasia type 1 (MEN-1) syndrome.
As noted above, omeprazole provides effective control ofsymptoms related to acid
secretion in ZES [21], but decisions regarding treatment of the gastrinoma itself
remain controversial. Hirschowitz counsels aconservative approach to the treatment
of the gastrinoma, based on his experience that the tumor itself rarely causes the
death of the patient. The approach taken at the NIH has been based on a more
aggressive approach to the tumor [22].
What do the naturally occurring paradigms ofhypergastrinemia, such as ZES and
atrophicgastritis, and the long-term clinical studies [23,24] with omeprazole teach us
regarding the clinical risks of proton pump inhibition with respect to alterations in
ECL cells? At this point, there appears to be no risk from short-term use and
minimal, if any risk, from use of longer duration, although additional data are
required to buttress this conclusion. Further information regarding this important
issue isprovided in the section ofthesymposiumspecificallyaddressing the ECLcell.
As evidenced by the papers in this section, our in-depth knowledge of certain
focused areas has dramatically enhanced our ability to understand and intervene in
acid peptic disease. What is unknown is substantial however, and future advances
will be based on broadening our knowledge.
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